Response to checkpoint therapy has been positively correlated with tumor mutational burden (TMB) and with presence of CD8+ T cells in the tumor microenvironment (characterized as “hot” tumors) (Yarchoan et al., 2017) (Tumeh et al., 2014). The gene discussed is CD8A; the disease is neoplasm.